Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin.
Journal: Antimicrobial agents and chemotherapy
Published: August 27, 2026
Acute blood pressure reduction exceeding safety and autoregulatory limits following rapid-acting antihypertensives for hypertensive urgency.
Journal: Journal of hypertension
Published: October 10, 2025
Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial.
Journal: Cancer chemotherapy and pharmacology
Published: January 02, 2025
Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics.
Journal: Journal of clinical pharmacology
Published: December 18, 2023
Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study.
Journal: Journal of Cancer
Published: January 17, 2023
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
Journal: Clinical pharmacology and therapeutics
Published: March 15, 2022
Characterization of Potassium-Induced Natriuresis in Hypertensive Postmenopausal Women During Both Low and High Sodium Intake.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: January 20, 2022
Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
Journal: Journal of clinical pharmacology
Published: May 10, 2021
Thiazide-Sensitive NCC (Sodium-Chloride Cotransporter) in Human Metabolic Syndrome: Sodium Sensitivity and Potassium-Induced Natriuresis.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: January 04, 2021
Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
Journal: Journal of clinical pharmacology
Published: July 30, 2020
Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment.
Journal: Clinical pharmacology in drug development
Published: July 13, 2020
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment.
Journal: Leukemia & lymphoma
Published: February 08, 2020
Last Updated: 09/26/2026